Adefovir dipivoxil and pegylated interferon alpha for the treatment of chronic hepatitis B: an updated systematic review and economic evaluation

INIS

• biochemical activity 5%
• comparative evaluations 31%
• cost 42%
• damage 5%
• data 5%
• discount rate 5%
• dna 5%
• drugs 15%
• economics 21%
• evaluation 21%
• fibrosis 5%
• gain 5%
• hepatitis 26%
• interferon 100%
• levels 10%
• libraries 5%
• liver 10%
• markov process 5%
• patients 10%
• probabilistic estimation 10%
• probability 5%
• range 5%
• reviews 21%
• screening 5%
• sensitivity analysis 15%
• therapy 5%
• utilities 5%
• values 5%

Pharmacology, Toxicology and Pharmaceutical Science

• Adefovir Dipivoxil 78%
• Adverse Event 5%
• Alpha Interferon 5%
• Alpha2a Interferon 31%
• Antivirus Agent 10%
• Chronic Hepatitis B 26%
• Combination Therapy 5%
• DNA 5%
• Drug 10%
• Drug Resistance 5%
• Hepatitis B(e) Antigen 5%
• Lamivudine 36%
• Life Expectancy 5%
• Liver Fibrosis 5%
• Liver Injury 5%
• Monotherapy 21%
• Peginterferon Alpha 52%
• Peginterferon Alpha2b 42%
• Placebo 10%
• Randomized Controlled Trial 31%

Biochemistry, Genetics and Molecular Biology

• Cochrane Library 5%
• DNA 5%
• Drug Resistance 5%
• HBeAg 5%
• Interferon 100%
• Screening 5%
• Sensitivity Analysis 15%
• Taxonomy 10%
• Virus Load 5%